Eudaimonia Partners’s Heron Therapeutics HRTX Stock Holding History

Eudaimonia Partners’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-600	Closed	-$10K	–	799
2021 Q1	$10K	Buy	+600	New	+$10.7K	﹤0.01%	1160

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Eudaimonia Partners's HRTX Position: Q2 2021 in Review

Eudaimonia Partners sold out of Heron Therapeutics (HRTX) in Q2 2021, closing a stake of 600 shares — an estimated $10K sold.

Eudaimonia Partners first reported a position in HRTX in Q1 2021 and held it in 1 quarter. The position peaked at $10K in Q1 2021. 189 funds tracked by Wall St. Rank hold HRTX as of Q2 2021.

Eudaimonia Partners reported no remaining Heron Therapeutics position as of Q2 2021 after selling out during the quarter.
Eudaimonia Partners sold 600 Heron Therapeutics shares in Q2 2021, an estimated $10K.
Eudaimonia Partners first reported a position in Heron Therapeutics in Q1 2021 and held it in 1 quarter.
Eudaimonia Partners's Heron Therapeutics position peaked at $10K in Q1 2021.
189 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.